Literature DB >> 16382465

Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome.

Kymberly D S Watt1, Elizabeth R Lyden, James M Gulizia, Timothy M McCashland.   

Abstract

Organ cold/warm ischemia is thought to be a risk factor for increased severity of recurrence of hepatitis C (HCV) post liver transplantation. We had noted some HCV patients with preservation injury (PI) to have particularly poor outcomes. Our goal was to determine if PI on biopsy in HCV patients is associated with earlier, more rapidly progressive recurrence or graft and patient survival. Sixty-nine patients from the University of Nebraska transplant database were included: 23 HCV patients with PI (group = 1), 23 non-HCV patients with PI (group = 2), and 23 HCV patients without PI (group = 3). Patient groups were matched for gender, age, immunosuppression, and time of transplantation for analysis. No difference in time to recurrence was noted between HCV groups (256 vs. 316 days posttransplant). More patients in group 1 had progression to stage 3 or 4 fibrosis, compared to group 3 (43 vs. 9%, P = 0.02). One-year survival for groups 1, 2, and 3 was 78, 82, and 100% respectively, whereas 3-yr survival was 59, 82, and 88% (group 1 vs. group 2 or 3 respectively, P = 0.0055). There was no difference in survival between groups 2 and 3. Patients in group 1 that received antiviral treatment had improved survival, compared to those who did not (P = 0.012). Risk factors for poor survival on univariate analysis included severity of PI (Relative Risk = 2.78, P < 0.001) and donor age of >55 (P = 0.014). Multivariate analysis shows HCV is the most important factor. In conclusion, HCV transplant patients with evidence of early PI on biopsy have poorer survival outcomes than non-HCV transplant patients with PI or HCV transplant patients without PI. Consideration for antiviral therapy early in the posttransplant course may be warranted in this subset of patients. Copyright 2005 AASLD

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16382465     DOI: 10.1002/lt.20583

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  20 in total

Review 1.  Recurrent hepatitis C after liver transplant.

Authors:  Andrew S deLemos; Paul A Schmeltzer; Mark W Russo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.

Authors:  Kymberly D S Watt; Kelly Burak; Marc Deschênes; Les Lilly; Denis Marleau; Paul Marotta; Andrew Mason; Kevork M Peltekian; Eberhard L Renner; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

Review 3.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation.

Authors:  Vijay Subramanian; Anil B Seetharam; Neeta Vachharajani; Venkataswarup Tiriveedhi; Nataraju Angaswamy; Sabarinathan Ramachandran; Jeffrey S Crippin; Surendra Shenoy; William C Chapman; Thalachallour Mohanakumar; Christopher D Anderson
Journal:  Transplantation       Date:  2011-12-15       Impact factor: 4.939

Review 5.  Using old liver grafts for liver transplantation: where are the limits?

Authors:  Carlos Jiménez-Romero; Oscar Caso Maestro; Félix Cambra Molero; Iago Justo Alonso; Cristina Alegre Torrado; Alejandro Manrique Municio; Jorge Calvo Pulido; Carmelo Loinaz Segurola; Enrique Moreno González
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

6.  The clinical consequences of utilizing donation after cardiac death liver grafts into hepatitis C recipients.

Authors:  Mohammad Mawardi; Faisal Aba Alkhail; Kazuhiro Katada; Mark Levstik; Douglas Quan; William Wall; Paul Marotta; Roberto Hernandezalejandro
Journal:  Hepatol Int       Date:  2011-01-15       Impact factor: 6.047

7.  Effect of nonviral factors on hepatitis C recurrence after liver transplantation.

Authors:  Andrew M Cameron; Rafik M Ghobrial; Jonathan R Hiatt; Ian C Carmody; Sherilyn A Gordon; Douglas G Farmer; Hasan Yersiz; Michael A Zimmerman; Francisco Durazo; Steve H Han; Sammy Saab; Jeffrey Gornbein; Ronald W Busuttil
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

8.  Strategies to reduce hepatitis C virus recurrence after liver transplantation.

Authors:  Ruben Ciria; María Pleguezuelo; Shirin Elizabeth Khorsandi; Diego Davila; Abid Suddle; Hector Vilca-Melendez; Sebastian Rufian; Manuel de la Mata; Javier Briceño; Pedro López Cillero; Nigel Heaton
Journal:  World J Hepatol       Date:  2013-05-27

9.  Prevention of hepatitis C recurrence after liver transplantation: An update.

Authors:  Marco Carbone; Ilaria Lenci; Leonardo Baiocchi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

Review 10.  Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.

Authors:  Alberto Grassi; Giorgio Ballardini
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.